VISEN Pharma Repurchases 10,400 Shares, Lifts Treasury Stock to 107,800 Units

Bulletin Express06-10

VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD 19.71 and HKD 20.28 per share. The volume-weighted average repurchase price was approximately HKD 19.93.

\n\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell marginally by 0.009 % to 113.82 million shares, while total issued shares remained unchanged at 113.93 million. Treasury stock rose to 107,800 shares, equivalent to about 0.09 % of total issued shares.

\n\nThe repurchase forms part of VISEN Pharma’s mandate approved on 27 June 2025, which allows buybacks of up to 11.39 million shares. Cumulative purchases under this mandate now stand at 107,800 shares, representing 0.09 % of the share count on the mandate date. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 10 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172605583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172605583","market":"hk","top_or_hot":-1,"title":"VISEN Pharma Repurchases 10,400 Shares, Lifts Treasury Stock to 107,800 Units","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD 19.71 and HKD 20.28 per share. The volume-weighted average repurchase price was approximately HKD 19.93.</p>\n<p>\\n\\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell marginally by 0.009 % to 113.82 million shares, while total issued shares remained unchanged at 113.93 million. Treasury stock rose to 107,800 shares, equivalent to about 0.09 % of total issued shares.</p>\n<p>\\n\\nThe repurchase forms part of VISEN Pharma’s mandate approved on 27 June 2025, which allows buybacks of up to 11.39 million shares. Cumulative purchases under this mandate now stand at 107,800 shares, representing 0.09 % of the share count on the mandate date. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 10 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Repurchases 10,400 Shares, Lifts Treasury Stock to 107,800 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Repurchases 10,400 Shares, Lifts Treasury Stock to 107,800 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-10 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD 19.71 and HKD 20.28 per share. The volume-weighted average repurchase price was approximately HKD 19.93.</p>\n<p>\\n\\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell marginally by 0.009 % to 113.82 million shares, while total issued shares remained unchanged at 113.93 million. Treasury stock rose to 107,800 shares, equivalent to about 0.09 % of total issued shares.</p>\n<p>\\n\\nThe repurchase forms part of VISEN Pharma’s mandate approved on 27 June 2025, which allows buybacks of up to 11.39 million shares. Cumulative purchases under this mandate now stand at 107,800 shares, representing 0.09 % of the share count on the mandate date. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 10 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1172605583","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172605583","pubTimestamp":1781088305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharma回购10,400股，库存股增至107,800股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD 19.71 and HKD 20.28 per share. The volume-weighted average repurchase price was approximately HKD 19.93.\n\\n\\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell marginally by 0.009 % to 113.82 million shares, while total issued shares remained unchanged at 113.93 million. Treasury stock rose to 107,800 shares, equivalent to about 0.09 % of total issued shares.\n\\n\\nThe repurchase forms part of VISEN Pharma’s mandate approved on 27 June 2025, which allows buybacks of up to 11.39 million shares. Cumulative purchases under this mandate now stand at 107,800 shares, representing 0.09 % of the share count on the mandate date. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 10 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172605583","isCrawlerRequest":true}